H&T Presspart

Metal and Plastic Respiratory Drug Delivery Components and Devices

H&T Presspart's laboratory.

H&T Presspart specialises in the development of custom drug delivery components made from metal or plastic.

Optimising products from concept to delivery, the company studies and refines its processes to ensure optimum performance and quality.

Metered-dose inhaler (MDI) canisters and actuators

H&T Presspart has more than 45 years' experience of supplying metal metered-dose-inhalers (MDI), which are produced using the deep drawing method. The company offers a complete range of canisters including 10ml, 14ml, 17ml, and 19ml capacities designed for full compatibility with the actuator, valve, and drug formulation of the MDI.

H&T Presspart's canister portfolio is suitable for use with hydrofluoroalkane (HFA) and chlorofluorocarbon (CFC) propellants.

As one of the leading suppliers of MDI components, H&T Presspart produces a comprehensive range of MDI actuators, which are made from a wide range of plastic resins. One or two piece actuators are available for both solution and suspension formulations. Key features include tight dimensional tolerances, a reliable manufacturing process, and the ability to withstand extreme temperatures.

Plasma surface treatment technology for MDI canisters

H&T Presspart's sub-micron plasma surface treatment improves the surface energy performance of an MDI canister. This helps prevent deposition of active drug content on the canister wall to improve dosing efficiency and enhance drug stability performance, which ultimately helps extend shelf life and reduce product degradation.
Connected smart MDIs

Launched in partnership with Cohero Health, H&T Presspart's fully-connected electronic metered-dose inhaler (eMDI) is designed to improve adherence and optimise care for patients with asthma and chronic obstructive pulmonary disease (COPD). It incorporates Cohero Health's BreatheSmart management platform, which provides tracking of controller and rescue medications, as well as real-time, clinically accurate lung function measurement.

Easy-to-use capsule based dry powder inhaler

H&T Presspart's PowdAir Plus is a four-component, capsule-based dry powder inhaler (DPI), which is designed to be discreet. This easy-to-use device provides an accurate dose delivery in a simple and low-cost method.
The patented capsule is compact and portable. This simple and innovative DPI helps reduce manufacturing assembly and production costs, while maintaining a sleek and aesthetical design.

History of H&T Presspart

Since 1970, H&T Presspart has provided DPI devices from its manufacturing sites in Germany, the UK, and Spain. This is supported by effective sales offices in India, China, the US, and South America. In addition, the firm has been established as a leading partner to many of the world's largest pharmaceutical companies worldwide.

Contact Details

Presspart Manufacturing Ltd
Whitebirk Industrial Estate
United Kingdom
Contact: Chad Mayoh
+44 1254 582 233
+44 1254 584 100

Available White Papers


Connected Metered Dose Inhalers 18 October 2017 In this article, H&T Presspart's programme manager Benjamin Jung and US sales and business development director Dana Shears describe the role of connected devices in the treatment of asthma and COPD. They discuss the requirements for mass adoption and introduce their inhaler, the eDMI, which has connectivity fully enabled.


Modifying MDI Canister Surfaces to Improve Drug Stability and Delivery 05 October 2017 Hydrofluoroalkane (HFA) based propellants are widely used in modern metered-dose inhalers (MDI) due to their lack of hazardous and environmentally damaging effects.


Technological Developments Towards Consistent Respiratory Drug Delivery 13 April 2016 Devices for delivering drugs to the lungs have evolved considerably over the past few decades.


From Conception to Completion: Delivering Drugs of the Future 13 April 2016 Contract Manufacturing (CMO) has long been associated with the global pharmaceutical industry, primarily as outsourcing providers of finished medicines.


Optimising Metered Dose Inhalers for Respiratory Disorders 08 April 2016 Respiratory disorders affect hundreds of millions of people worldwide, with an estimated 300 million people suffering from asthma and a further 210 million with chronic obstructive pulmonary disease (COPD).